In summary, our study provides evidence that specific MPO residues are critical for BET and CCl binding and may be exploited for the use of these ligands for therapeutic purposes in myocardial ischemia (Figure 2, Figure 3, Figure 4 and Figure 5). This evidence concerns the gene MPO and myocardial ischemia.